Clinical Trial Update: Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. [Phase 3]

View source ↗

Summary

A phase 3 trial comparing lenalidomide plus rituximab followed by lenalidomide versus rituximab maintenance in relapsed/refractory follicular, marginal zone, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Celgene | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2025-07-10